Insight Molecular Diagnostics Inc. (IMDX) stock
IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$1.97+0.31 (+18.67%)
Close on Nov 20, 2026Market cap $64.47MP/E –Yield –
Insight Molecular Diagnostics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Insight Molecular Diagnostics's free cash flow for the twelve months ending Jun 30, 2026 was -$31.00M. For fiscal 2025 it was -$25.37M. The highest annual figure on record is -$1.17M in fiscal 2014.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$25.37M | – |
| FY2024 | Dec 31, 2024 | -$21.21M | – |
| FY2023 | Dec 31, 2023 | -$23.61M | – |
| FY2022 | Dec 31, 2022 | -$49.91M | – |
| FY2021 | Dec 31, 2021 | -$38.19M | – |
| FY2020 | Dec 31, 2020 | -$27.21M | – |
| FY2019 | Dec 31, 2019 | -$20.63M | – |
| FY2018 | Dec 31, 2018 | -$11.68M | – |
| FY2017 | Dec 31, 2017 | -$13.48M | – |
| FY2016 | Dec 31, 2016 | -$7.63M | – |
| FY2015 | Dec 31, 2015 | -$4.73M | – |
| FY2014 | Dec 31, 2014 | -$1.17M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$10.05M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.25M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.02M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.68M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.52M | – |
| Q1 FY2025 | Mar 31, 2025 | -$6.15M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.57M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.62M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.17M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.85M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.69M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.45M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.26M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.37M | – |
| Q1 FY2022 | Mar 31, 2022 | -$14.84M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.47M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.38M | – |
| Q2 FY2021 | Jun 30, 2021 | -$8.67M | – |
| Q1 FY2021 | Mar 31, 2021 | -$10.68M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.31M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.53M | – |
| Q2 FY2020 | Jun 30, 2020 | -$7.45M | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.91M | – |
| Q4 FY2019 | Dec 31, 2019 | -$6.21M | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.85M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.85M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.73M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.46M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.49M | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.97M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.76M | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.35M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.50M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.32M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.31M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.60M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.04M | – |
See a number that looks wrong?